Varex Imaging Corporation · NASDAQ:VREX

Varex Imaging — Q4 2021 Earnings Presentation

27 slides from Varex Imaging's earnings presentation, Nov 16, 2021

  1. Slide 1: Q4 FY21 Earnings Presentation

    Slide 1: Q4 FY21 Earnings Presentation

    Solutions in Sight® Q4 FY21 Earnings Presentation November 16, 2021 1

  2. Slide 2: Forward Looking Statements / Non-GAAP Measures

    Slide 2: Forward Looking Statements / Non-GAAP Measures

    Forward Looking Statements / Non-GAAP Measures Forward Looking Statements Certain statements in this supplement contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward looking statements incl

  3. Slide 3: Q4 FY21 Results

    Slide 3: Q4 FY21 Results

    Q4 FY21 Results Non-GAAP Non-GAAP Revenue Cash Gross Margin* EPS* $226M $145M 34% $0.45  Strong demand drives record revenue  Profitability enabled by improved operating leverage  Robust cash generation of $45M  Supply chain constrained challenges continued * Non-GAAP. For a reconciliation to th

  4. Slide 4: Q4 FY21 Sequential Trends

    Slide 4: Q4 FY21 Sequential Trends

    Q4 FY21 Sequential Trends CT Mammography Radiography & Fluoroscopy Others Oncology Industrial Dental 4

  5. Slide 5: Quarterly Highlight: AI-aided Software

    Slide 5: Quarterly Highlight: AI-aided Software

    Quarterly Highlight: AI-aided Software Portfolio of AI-aided Software  >50% of $30M+ software platform  Focus on investment in growing AI market  Innovation through various clinical competences  Cloud-based solution 5

  6. Slide 6: Lung Cancer Screening Software

    Slide 6: Lung Cancer Screening Software

    Lung Cancer Screening Software Background – Lung Cancer in the USA  200,000+ lung cancer cases & 60,000 deaths per year1  Eligible candidates in US doubling to >15 million per year  Late diagnosis increases risk – 18.6% survival rate2  LDCT screening with AI-aided diagnosis  Reimbursable under

  7. Slide 7: CT Lung Screening Workstation: Veolity LungRead

    Slide 7: CT Lung Screening Workstation: Veolity LungRead

    CT Lung Screening Workstation: Veolity LungRead Stand-alone lung reading and reporting solution  Diagnostic Quality: AI-aided detection of pulmonary nodules (CAD)  Faster Radiologist Reading: Automated workflow, temporal comparison  Precision Diagnostics: Automated measurements  Patient Follow-u

  8. Slide 8: Lung Screening Market

    Slide 8: Lung Screening Market

    Lung Screening Market Market Growth: ~20% CAGR through 2025 2021 Market: ~$20M* Installed base: >570 *Includes Workstation and CAD, as well as reporting and analysis tools Note; Green circles represent installed base locations 8

  9. Slide 9: FY2021 vs. FY2019

    Slide 9: FY2021 vs. FY2019

    FY2021 vs. FY2019 Revenue Adjusted EBITDA +5% +15% $818 $133 $781 $116 FY2019 FY2021 FY2019 FY2021 Note: $millions 9

  10. Slide 10: Robust Growth Trajectory

    Slide 10: Robust Growth Trajectory

    Robust Growth Trajectory $240 $50.0 $226 $45.0 $220 $211 $40.0 $202 $204 $39 $40 $200 $35.0 $200 $196 $197 $197 $33 $33 $186 $30.0 $30 $177 $180 $25.0 $27 $26 $171 $170 $24 $22 $20.0 $160 $19 $15.0 $10.0 $140 $5.0 $5 $4 $120 $0.0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 Sales Adju

  11. Slide 11: FY2021 – Record Performance

    Slide 11: FY2021 – Record Performance

    FY2021 – Record Performance Revenue Gross Margin Adjusted EBITDA +11% +470 bps +2.5x $818 34.7% $133 $738 30.0% $52 FY2020 FY2021 FY2020 FY2021 FY2020 FY2021 Non-GAAP Diluted EPS Operating Cash Flow 18x +$80M $93 $1.31 $13 $0.07 FY2020 FY2021 FY2020 FY2021 Note: $millions except for per share data 1

  12. Slide 12: Q4 FY21 Revenue Details

    Slide 12: Q4 FY21 Revenue Details

    Q4 FY21 Revenue Details Segment Mix Geographic Mix ($ in millions) ($ in millions) $46 $70 $82 $181 $74 Medical Industrial Americas EMEA APAC Revenue, $M Q4 21 Q3 21 Q2 21 Q1 21 Q4 20 Revenue, $M Q4 21 Q3 21 Q2 21 Q1 21 Q4 20 Medical 181 167 157 139 136 Americas 70 66 71 62 64 Industrial 46 44 47 38

  13. Slide 13: Quarterly Results - GAAP

    Slide 13: Quarterly Results - GAAP

    Quarterly Results - GAAP $ in Millions, except per share data Q4 FY21 Q3 FY21 Q4 FY20 Revenue $226 $211 $170 Gross Margin 33% 35% 27% $49 $48 $58 Operating Expenses 22% 23% 34% $27 $26 $(13) Operating Income 12% 12% (8)% Net Earnings $9 $12 $(26) EPS, diluted $0.20 $0.29 $(0.68) Avg. shares, diluted

  14. Slide 14: Quarterly results – Non-GAAP

    Slide 14: Quarterly results – Non-GAAP

    Quarterly results – Non-GAAP* $ in Millions, except per share data Q4 FY21 Q3 FY21 Q4 FY20 Revenue $226 $211 $170 Gross Margin (Non-GAAP) 34% 36% 28% $45 $46 $48 Operating Expenses (Non-GAAP) 20% 22% 28% $33 $30 $(1) Operating Income (Non-GAAP) 14% 14% (0)% Net Earnings (Non-GAAP) $19 $16 $(2) EPS,

  15. Slide 15: Select Balance Sheet Data

    Slide 15: Select Balance Sheet Data

    Select Balance Sheet Data $ in Millions Q4 FY21 Q3 FY21 Q4 FY20 Assets Cash and Cash Equivalents $145 $128 $101 Accounts Receivable, net $155 $148 $124 Inventories $225 $243 $272 Total Assets $1,148 $1,161 $1,140 Liabilities Accounts Payable $59 $66 $73 Long-Term Debt, net $435 $463 $455 Total Liabi

  16. Slide 16: Select Debt and Cash Flow Data

    Slide 16: Select Debt and Cash Flow Data

    Select Debt and Cash Flow Data $ in Millions Q4 FY21 Q3 FY21 Q4 FY20 Debt Gross Debt $481 $512 $511 (Ratings: Moody’s B2 / S&P B+) Net Debt1 $336 $383 $410 Adjusted EBITDA2 Adjusted EBITDA $40 $39 $4 Cash Performance Cash Flow from Operations $51 $22 ($12) Capital Expenditures $3 $5 $4 Cash Interest

  17. Slide 17: Outlook Q1 FY22

    Slide 17: Outlook Q1 FY22

    Outlook Q1 FY22 Guidance Non-GAAP Revenues, $M $200 - $220 EPS Per Diluted Share $0.20 - $0.40 Assumptions Non-GAAP Gross Margin 34% - 35% Operating Expenses, $M $45 - $46 17

  18. Slide 18: Solutions in Sight®

    Slide 18: Solutions in Sight®

    W VAREA Solutions in Sight®

  19. Slide 19: Non-GAAP Reconciliation

    Slide 19: Non-GAAP Reconciliation

    Solutions in Sight® Non – GAAP Reconciliation 19

  20. Slide 20: Reconciliation between GAAP and Non-GAAP Financial measures (unaudited)

    Slide 20: Reconciliation between GAAP and Non-GAAP Financial measures (unaudited)

    Reconciliation between GAAP and Non-GAAP Financial measures (unaudited) Three Months Ended Twelve Months Ended October 1, October 2, October 1, October 2, (In millions, except per share amounts) 2021 2020 2021 2020 GROSS PROFIT RECONCILIATION Revenues $ 226.3 $ 170.0 $ 818.1 $ 738.3 Gross profit $ 7

  21. Slide 21: Reconciliation between GAAP and Non-GAAP Financial measures (unaudited)

    Slide 21: Reconciliation between GAAP and Non-GAAP Financial measures (unaudited)

    Reconciliation between GAAP and Non-GAAP Financial measures (unaudited) Three Months Ended Twelve Months Ended October 1, October 1, October 2, (In millions, except per share amounts) 2021 October 2, 2020 2021 2020 SELLING, GENERAL AND ADMINISTRATIVE EXPENSE RECONCILIATION Selling,general and admini

  22. Slide 22: Reconciliation between GAAP and Non-GAAP Financial measures (unaudited)

    Slide 22: Reconciliation between GAAP and Non-GAAP Financial measures (unaudited)

    Reconciliation between GAAP and Non-GAAP Financial measures (unaudited) Three Months Ended Twelve Months Ended October 1, October 2, October 1, October 2, (In millions, except per share amounts) 2021 2020 2021 2020 OPERATING INCOME (LOSS) RECONCILIATION Operating income (loss) $ 26.5 $ (12.9) $ 74.1

  23. Slide 23: Reconciliation between GAAP and Non-GAAP Financial measures (unaudited)

    Slide 23: Reconciliation between GAAP and Non-GAAP Financial measures (unaudited)

    Reconciliation between GAAP and Non-GAAP Financial measures (unaudited) Three Months Ended Twelve Months Ended October 2, (In millions, except per share amounts) October 1, 2021 2020 October 1, 2021 October 2, 2020 INCOME (LOSS) BEFORE TAXES RECONCILIATION Income (loss) before taxes $ 14.8 $ (30.5)

  24. Slide 24: Reconciliation between GAAP and Non-GAAP Financial measures (unaudited)

    Slide 24: Reconciliation between GAAP and Non-GAAP Financial measures (unaudited)

    Reconciliation between GAAP and Non-GAAP Financial measures (unaudited) Three Months Ended Twelve Months Ended (In millions, except per share amounts) October 1, October 2, October 1, October 2, 2021 2020 2021 2020 DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING RECONCILIATION GAAP weighted average comm

  25. Slide 25: Effect of Convertible Loan and Warrants on Diluted Share count

    Slide 25: Effect of Convertible Loan and Warrants on Diluted Share count

    Effect of Convertible Loan and Warrants on Diluted Share count Incremental Diluted Shares Share GAAP Non-GAAP Price* Shares Shares $25.00 1,619,210 9,610 $26.00 2,296,132 378,840 $27.00 2,922,913 720,720 $28.00 3,504,923 1,038,180 $29.00 4,046,794 1,333,746 $30.00 4,552,541 1,609,608 $31.00 5,025,65

  26. Slide 26: Discussion of Non – GAAP Financial Measures

    Slide 26: Discussion of Non – GAAP Financial Measures

    Discussion of Non – GAAP Financial Measures This presentation includes non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings. These measures are not presented in accordance with, nor are they a substitute for U.S. generally accepted accounting principles, or GAAP

  27. Slide 27: Solutions in Sight®

    Slide 27: Solutions in Sight®

    \ if VAREX . Solutions in Sight®

Source: Internet Archive copy of vareximaging.com

More decks from Varex Imaging Corporation

All 25 Varex Imaging decks